Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Our innovation technologies optimize your drug discovery programs to make them faster and more reliable
For more than 25 years, Oncodesign has been investing in precision medicine research technologies, which are essential from the very first stages of the Drug Discovery process. Our technology modules allow a continuum from molecule to patient, with the goal of discovering new treatments for patients with no therapeutic options.